Madrigal Pharmaceuticals, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Madrigal Pharmaceuticals, Inc. (MDGL) holds an ST Score of 51.6 out of 100 (C+), with its strongest factor being Momentum (A+) and its weakest Financial Strength (D). Analysts rate MDGL Buy across 25 ratings with a $677.00 average price target (+0.3% vs the current $531.52).
- Strongest
- MomentumA+
- Weakest
- Financial StrengthD
All factor grades
- MomentumA+
- ForecastB+
- GrowthB
- ProfitabilityB-
- ValuationC
- Financial StrengthD
- Piotroski2/9
Contact
MDGL stock: frequently asked questions
What is MDGL's ST Score?
Madrigal Pharmaceuticals, Inc. (MDGL) has an ST Score of 51.6 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is MDGL a buy, sell, or hold?
Wall Street's consensus rating on MDGL is Buy based on 25 analyst ratings. Our own ST Score grades it C+ (51.6/100). This is data, not investment advice — always do your own research.
What is MDGL's valuation grade?
Madrigal Pharmaceuticals, Inc. (MDGL) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is MDGL's growth grade?
Madrigal Pharmaceuticals, Inc. (MDGL) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is MDGL's profitability grade?
Madrigal Pharmaceuticals, Inc. (MDGL) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is MDGL's financial strength grade?
Madrigal Pharmaceuticals, Inc. (MDGL) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for MDGL?
The average analyst price target for Madrigal Pharmaceuticals, Inc. (MDGL) is $677.00 from 25 analysts, which is +0.3% versus the recent price of $531.52.
What is MDGL's Piotroski score?
Madrigal Pharmaceuticals, Inc. (MDGL) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.